PIPE-505 : Pipeline Therapeutics initiates phase 1/2a SNHL trial

Pipeline Therapeutics has initiated a phase 1/2a trial of PIPE-505, which is a small molecule gamma secretase inhibitor (GSI), in patients who have sensorineural hearing ... Read More